As with IFN therapy, older age, male sex, liver fibrosis, and posttreatment alpha-fetoprotein (AFP) levels are factors related to HCC development after DAA therapy14–16; dysplastic nodules17 and posttreatment M2BPGi18 have also been reported as factors. This evidence concerns the gene AFP and hepatocellular carcinoma.